CAS NO: | 1354707-41-7 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Mitochonic acid 5 bindsmitochondriaand ameliorates renal tubular and cardiac myocyte damage. Mitochonic acid 5 modulatesmitochondrial ATPsynthesis. | ||||||||||||||||
IC50& Target | Mitochondrial Metabolism[1] | ||||||||||||||||
体外研究 (In Vitro) | Mitochonic acid 5 (MA-5) modulates mitochondrial ATP synthesis independently of oxidative phosphorylation and the electron transport chain. Mitochondrial dysfunction causes increased oxidative stress and depletion of ATP, which are involved in the etiology of a variety of renal diseases[1]. Mitochonic acid 5 (MA-5), which is derived from the plant growth hormone indole-3-acetic acid, can protect mitochondrial function by regulating energy metabolism and reducing mitochondrial oxidative stress. To observe the protective role of Mitochonic acid 5 in microglia under inflammatory conditions, TNFα is applied. Subsequently, the MTT assay is used to evaluate cell viability. In response to the TNFα treatment, cell viability significantly decreases. However, this effect is dose-dependently inhibited by Mitochonic acid 5 treatment[2]. | ||||||||||||||||
体内研究 (In Vivo) | Administration of Mitochonic acid 5 (MA-5) to an ischemia-reperfusion injury model and a cisplatin-induced nephropathy model improved renal function. To examine the tissue-protective effect of Mitochonic acid 5, the oral bioavailability is examined. Oral administration of Mitochonic acid 5 increases the plasma concentration in a dose-response manner at the peak time of 1 hour[1]. | ||||||||||||||||
分子量 | 329.30 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C18H13F2NO3 | ||||||||||||||||
CAS 号 | 1354707-41-7 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 106.66 mg/mL(323.90 mM) H2O :< 0.1 mg/mL(insoluble) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|